TARS
Tarsus Pharmaceuticals Inc
76.00$
+2.2%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 20.1% | 9.3% | 6.0% | 7.4% | 6.7% | 7.4% | 6.7% | 6.1% | 20.7% | 7.2% | 5.8% | 7.0% | 9.4% | |
| 79.9% | 90.7% | 94.0% | 92.6% | 93.3% | 92.6% | 93.3% | 93.9% | 79.3% | 92.8% | 94.2% | 93.0% | 90.6% | |
| 647.0% | 101.8% | 43.7% | 30.2% | 25.2% | 25.4% | 18.4% | 15.2% | 13.7% | 11.9% | 13.8% | 17.8% | 14.5% | |
| 1,620.7% | 502.4% | 186.8% | 144.1% | 120.3% | 103.9% | 108.5% | 100.3% | 91.5% | 86.2% | 84.2% | 86.7% | 86.8% | |
| 2,267.7% | 430.6% | 230.5% | 174.2% | 145.6% | 129.4% | 126.9% | 115.5% | 91.5% | 98.1% | 98.0% | 104.5% | 98.6% | |
| -2,187.9% | -339.9% | -136.5% | -81.6% | -52.3% | -36.8% | -33.5% | -21.6% | -12.2% | -5.3% | -3.8% | -11.4% | -8.0% | |
| 45.9% | 7.6% | 3.6% | 5.2% | 4.8% | 3.3% | 2.6% | 2.0% | 1.8% | 1.5% | 1.3% | 1.2% | 1.4% | |
| -2,092.4% | -320.4% | -129.4% | -81.6% | -48.7% | -34.8% | -32.1% | -19.8% | -10.6% | -4.2% | -5.8% | -9.1% | -7.3% | |
| -95.5% | 232.5% | -1.0% | – | – | – | – | – | – | 1.4% | -1.5% | 1.6% | – | |
| -2,092.4% | -320.4% | -129.4% | -81.6% | -48.7% | -34.8% | -32.1% | -19.8% | -10.6% | -5.5% | -4.3% | -10.7% | -7.7% | |
| -2,035.2% | -310.2% | -124.9% | -75.8% | -43.0% | -30.7% | -28.7% | -17.2% | -10.2% | -2.4% | -4.2% | -7.3% | -5.8% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.